Neurotechnology is a broad category of devices and systems designed to read, interpret, or influence activity in the brain and nervous system. It spans everything from the EEG caps used in hospital sleep labs to experimental implants that let paralyzed patients control a computer cursor with their thoughts. The global neurotechnology market is valued at roughly $16 billion in 2025 and is projected to exceed $33 billion by 2031, driven by advances in computing power, miniaturized sensors, and a growing understanding of how the brain encodes information.
How Neurotechnology Works
At the most basic level, your neurons communicate through tiny electrical and chemical signals. Neurotechnology taps into those signals in one of two directions: it either reads them (recording what the brain is doing) or writes them (delivering energy to change what the brain is doing). Some systems do both at once.
A brain-computer interface, or BCI, is a good example of the reading side. It captures raw brain signals, filters out noise, identifies meaningful patterns in the data, classifies what those patterns represent (like the intention to move a hand), and then sends a corresponding command to an external device. That pipeline, from signal to action, happens in five stages: acquisition, preprocessing, feature extraction, classification, and device control. Every BCI follows this basic sequence whether it sits on your scalp or is surgically placed on the brain’s surface.
Non-Invasive Tools
Non-invasive neurotechnologies sit outside the body, typically on the scalp, and require no surgery. They are by far the most widely used category.
EEG (electroencephalography) uses electrodes placed on the scalp to detect voltage changes produced by large groups of neurons firing together. Its standout feature is speed: it captures brain activity with millisecond precision, making it excellent for tracking fast-changing mental states. The trade-off is blurry spatial detail. Standard EEG can tell you something is happening in the general area of your left frontal lobe, but not exactly where. High-density systems with 128 or 256 channels improve that resolution considerably and are now used in brain-computer interfaces, epilepsy mapping, and stroke rehabilitation monitoring.
fNIRS (functional near-infrared spectroscopy) takes a different approach. It shines near-infrared light through the skull and measures changes in blood oxygen levels in the cortex. When a brain region becomes more active, it draws more oxygenated blood, and fNIRS picks up that shift. It offers better spatial resolution than EEG and holds up well during movement, making it practical for studying people while they walk, exercise, or perform rehabilitation tasks. Its weakness is temporal resolution: it’s slower than EEG because it’s tracking blood flow, which lags behind electrical activity by a few seconds.
Transcranial stimulation sits on the “writing” side. Devices like transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) deliver magnetic pulses or weak electrical currents through the skull to either excite or quiet specific brain regions. These are already used clinically for treatment-resistant depression and are being studied for chronic pain, stroke recovery, and cognitive enhancement.
Researchers increasingly combine these tools. Pairing EEG and fNIRS, for instance, gives both the fast temporal detail of electrical recording and the sharper spatial picture of blood-flow imaging, compensating for each technology’s individual blind spots.
Invasive Implants and BCIs
Invasive neurotechnology involves placing devices directly on or inside the brain. The signal quality is dramatically better than anything captured through the skull, but the surgery carries real risks, including infection and tissue scarring.
Deep brain stimulation (DBS) is the most established invasive approach. Thin electrodes are implanted into specific brain structures and connected to a battery-powered pulse generator, similar to a pacemaker, placed under the skin near the collarbone. In Parkinson’s disease, DBS delivers continuous electrical pulses that disrupt the abnormal signaling responsible for tremor and stiffness. Long-term follow-up data show that tremor responds best, with about 73% of patients reporting improvement, and satisfaction remains remarkably high: more than 92% of patients say they’re happy with the device, and 95% would recommend it to others, even after a decade. DBS doesn’t stop Parkinson’s from progressing, but it provides durable symptom control that helps many people maintain daily activities like dressing and running errands for years.
Brain-computer interfaces represent the newer frontier. Neuralink’s N1 implant is currently in an early feasibility study, with seven patients enrolled at sites in the UK. The trial is evaluating safety and basic functionality for people with paralysis, with the goal of restoring some degree of independence through thought-controlled computer use. Synchron, another BCI company, uses a different approach: its device is threaded through a blood vessel into the brain, avoiding open surgery altogether. These trials are still in early phases, meaning the technology is being tested primarily for safety rather than broad effectiveness.
Medical Applications Beyond Movement
Neurotechnology’s medical footprint extends well beyond Parkinson’s and paralysis. In stroke rehabilitation, EEG and fNIRS are used to monitor how the brain reorganizes itself during recovery. Clinicians track metrics like how symmetrical electrical activity is between the two brain hemispheres and whether motor regions are regaining normal connectivity. These measurements help predict who will recover well and guide adjustments to therapy plans.
Imaging techniques like diffusion tensor imaging (DTI), which maps the brain’s white matter pathways, can predict motor recovery up to 12 months after a stroke, particularly for patients with severe initial impairment. That kind of early forecasting helps clinicians set realistic goals and allocate intensive therapy to the patients most likely to benefit from it.
Epilepsy treatment has also been transformed. High-density EEG helps pinpoint where seizures originate, guiding surgical decisions. Responsive neurostimulation devices can now detect the electrical signature of an oncoming seizure and deliver a targeted pulse to stop it before symptoms begin. Cochlear implants, one of the earliest and most successful neurotechnologies, bypass damaged hair cells in the inner ear and stimulate the auditory nerve directly, restoring functional hearing for hundreds of thousands of people worldwide.
Consumer and Wellness Uses
A growing number of neurotechnology products target healthy consumers rather than patients. EEG-based headbands marketed for meditation use simplified brainwave readings to give you real-time feedback on your mental state, nudging you toward calmer patterns. Neurofeedback programs claim to improve focus, sleep, or stress management by training you to consciously shift your own brain activity.
The evidence behind many consumer devices is thinner than what supports clinical neurotechnology. A medical-grade EEG system might use 64 to 256 electrodes and undergo rigorous validation. A consumer headband typically uses fewer than 10 sensors and may not have been tested in controlled trials for the specific benefits it advertises. That doesn’t mean these products are useless, but the gap between clinical-grade and consumer-grade neurotechnology is significant.
Privacy and the Question of “Neurorights”
As neurotechnology becomes capable of decoding increasingly detailed information about what a person is thinking, feeling, or intending, questions about brain data privacy have moved from philosophy seminars into legislatures. Chile became the first country to pass a constitutional amendment addressing “neurorights,” adding protections for mental integrity and brain-generated data. The law was a landmark, but its practical application has already proven complicated. A Chilean Supreme Court case revealed tensions in how the law interacts with existing data protection rules, and legal scholars have noted that current privacy frameworks, even relatively new ones like the EU’s data regulations, weren’t designed to handle the unique characteristics of neural data.
The core concern is straightforward: brain data is qualitatively different from other personal information. Your neural activity patterns can reveal not just what you’ve done but what you’re considering doing, how you feel about it, and whether you’re telling the truth. If neurotechnology companies collect and store that data, the potential for misuse goes beyond anything conventional data breaches involve. Several countries and international bodies are now developing governance frameworks, but regulation is moving far slower than the technology itself.